Pilocarpine

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O

InChI

InChIKey=QCHFTSOMWOSFHM-WPRPVWTQSA-N

InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf

Pilocarpine is an alkaloid extracted from plants of the genus Pilocarpus. The drug stimulates the muscarinic receptors (especially M3, which is expressed in smooth muscles and glands) and thus induces salivation, hypertension and water intake. Pilocarpine was appoved by FDA for the alleviation of symptoms of xerostomia in patients who have undergone radiation therapy to their head and neck cancer and in patients with Sjogren's Syndrome. Ophthalmic solution of the drug is prescribed for the treatment of glaucoma, ocular hypertension, postoperative elevated intraocular pressure, etc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 158 Target ID: P20309 Gene ID: 1131.0 Gene Symbol: CHRM3 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/11392632	Agonist 2662

Conditions

Condition	Modality	Highest Phase	Product
Head and neck cancer 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Secondary	Approved 8360	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 7.642944E11
Sjogren's syndrome 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Palliative	Approved 8360	SALAGEN Approved Use SALAGEN Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Launch Date 7.642944E11
Open-angle glaucoma 51 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8360	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 1.27716478E12
Ocular hypertension 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8360	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 1.27716478E12
Acute angle-closure glaucoma 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200890s001lbl.pdf	Primary	Approved 8360	ISOPTO CARPINE Approved Use Isopto Carpine is a muscarinic cholinergic agonist indicated for (1) the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; (2) the management of acute angle-closure glaucoma; (3) the prevention of postoperative elevated IOP associated with laser surgery; (4) the induction of miosis. Launch Date 1.27716478E12

C_max

Value	Dose	Co-administered	Analyte	Population
15 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
33 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	5 mg 3 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PILOCARPINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	Disc. AE: Vision blurred... AEs leading to discontinuation/dose reduction: Vision blurred (moderate, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36
20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	Other AEs: Increased salivation, Lacrimation... Other AEs: Increased salivation (1 patient) Lacrimation (1 patient) Vomiting (1 patient) Anxiety (1 patient) Tremor (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
100 mg single, oral Overdose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	unhealthy n = 2 Health Status: unhealthy Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf
1.54 % 3 times / day multiple, topical Recommended Dose: 1.54 %, 3 times / day Route: topical Route: multiple Dose: 1.54 %, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	unhealthy n = 20 Health Status: unhealthy Condition: xerostomia Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/	Sources: https://pubmed.ncbi.nlm.nih.gov/32248594/

AEs

AE	Significance	Dose	Population
Vision blurred	moderate, 2 patients Disc. AE	2 % 4 times / day multiple, ophthalmic Recommended Dose: 2 %, 4 times / day Route: ophthalmic Route: multiple Dose: 2 %, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36	unhealthy, 44-75 years n = 2 Health Status: unhealthy Age Group: 44-75 years Sex: M Population Size: 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf Page: p. 36
Anxiety	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Increased salivation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Lacrimation	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Tremor	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850
Vomiting	1 patient	20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15093850	unhealthy, 46 years n = 1 Health Status: unhealthy Condition: xerostomia Age Group: 46 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15093850

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709	substrate 1010	substrate 1193

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 704 CYP3A 211 CYP2D1 6	esterase 70 CYP2A6 523 CYP1A2 1032 CYP2C19 985 CYP2E1 648 BCRP 555

Drug as perpetrator

Target	Modality	Activity
CYP3A 295	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510190/pdf/brjpharm00164-0104.pdf#page=3 Page: 3.0	moderate
CYP2A6 736	inhibitor 3240 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes [Ki 1 uM]
CYP2D1 8	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572744/	yes [Ki 360 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1032	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C19 985	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2C9 1010	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2D6 1193	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP2E1 648	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
CYP3A4 1709	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0	weak	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=20 Page: 20.0
BCRP 555	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/25755207/	yes
esterase 70	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes
CYP2A6 523	substrate 3326 Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0	yes	unlikely (co-administration study) Comment: Given the low systemic exposure following topical ocular administration of ISOPTO® Carpine, clinically relevant drug-drug interactions based on CYP450 interactions is not expected for ISOPTO Carpine Sources: https://www.fda.gov/media/79033/download#page=3 Page: 3.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00GRLD	https://www.aablocks.com/goods/Goods/detail?id=AA00GRLD
Acorn PharmaTech	ACN-035822	http://www.acornpharmatech.com/
Alfa Chemistry	AP92137	https://reagents.alfa-chemistry.com/product/pilocarpine-cas-92-13-7-18590.html
Alichem	69004656	http://www.alichem.com/en/products/92-13-7.html
Aurora Fine Chemicals LLC	A18.030.974	http://online.aurorafinechemicals.com/info?ID=A18.030.974
ChemMol	49426222	http://www.chemmol.com/chemmol/49426222.html
ChemMol	99173770	http://www.chemmol.com/chemmol/99173770.html
Chemspace	CSSB00016990803	https://chem-space.com/CSSB00016990803
Hairui	HR101326	http://www.hairuichem.com/en/product/54-71-7.html
Hairui	HR142167	http://www.hairuichem.com/en/product/92-13-7.html
LGC Standards	DRE-A16208380AL-100	https://www.lgcstandards.com/US/en/p/DRE-A16208380AL-100
LGC Standards	DRE-C16208380	https://www.lgcstandards.com/US/en/p/DRE-C16208380
Lab Network	LN00331142	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00331142
MolPort	MolPort-002-512-506	https://www.molport.com/shop/molecule-link/MolPort-002-512-506
OChem	12013	http://www.ocheminc.com/index.php?act=psearch&pid=092P137
R&D Chemicals	1835	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8154
Smolecule	S539680	http://www.smolecule.com/products/s539680
Smolecule	S772644	https://www.smolecule.com/products/s772644
THE BioTek	bt-278347	https://www.thebiotek.com/product/inhibitors/bt-278347
THE BioTek	bt-308560	https://www.thebiotek.com/product/others/bt-308560
abcr GmbH	AB167837	http://www.abcr.com/shop/en/AB167837
mcule	MCULE-2634151840	https://mcule.com/MCULE-2634151840/

PubMed

Title	Date	PubMed
Norepinephrine in treatment of ocular hypertension and glaucoma.	1975 Mar	1138682
[The effect of physiological and extreme irritants on zinc metabolism in pancreatic islets and hippocampus cells].	2001	11392117
Synchronized feeding as a "conditioned stimulus" for overt seizures in chronically (limbic) epileptic rats: a model for "psychogenic seizures" with complex partial epilepsy.	2001	11264918
A new medication for treatment of dry mouth in Sjögren's syndrome.	2001 Apr	11404944
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.	2001 Apr	11316102
2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats.	2001 Apr	11311893
Alkaline phosphatase activity in whitefly salivary glands and saliva.	2001 Apr	11304750
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome.	2001 Apr	11274068
Stress response to surgical procedures in the submandibular region and its influence on salivary secretion in mice.	2001 Apr	11269873
Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy.	2001 Apr 1	11283235
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy.	2001 Apr 17	11303773
Exploring the potential for subtype-selective muscarinic agonists in glaucoma.	2001 Apr 27	11392632
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001 Apr 27	11392629
Alteration of cardiovascular and neuronal function in M1 knockout mice.	2001 Apr 27	11392617
The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease.	2001 Aug	11389860
Beta-adrenergic blocker therapy and the trabecular meshwork.	2001 Feb	11372544
Randomized double blind, placebo-controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia.	2001 Feb	11336078
Brief successive temporal observational sampling as a possible indicator of daily overt seizure activity in epileptic rats.	2001 Feb	11322611
The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension.	2001 Feb	11318298
Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma.	2001 Feb	11318297
Normalization of spatial learning despite brain damage in rats receiving ketamine after seizure-induction: evidence for the neuromatrix.	2001 Feb	11293016
Do recurrent febrile convulsions decrease the threshold for pilocarpine-induced seizures? Effects of nitric oxide.	2001 Feb 28	11248357
Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function.	2001 Jan	11339622
[Dry mouth].	2001 Jan 31	11252939
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.	2001 Jul	11431452
Prophylactic effects of pilocarpine hydrochloride on xerostomia models induced by X-ray irradiation in rats.	2001 Jul	11422222
Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine.	2001 Jul	11396879
Defective fluid secretion and NaCl absorption in the parotid glands of Na+/H+ exchanger-deficient mice.	2001 Jul 20	11358967
Evaluation of spontaneous contamination of ocular medications.	2001 Jul-Aug	11399868
Activity-induced expression of common reference genes in individual cns neurons.	2001 Jun	11406652
Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours.	2001 Jun	11403176
Potential mechanism for the additivity of pilocarpine and latanoprost.	2001 Jun	11384567
Behavioral and electroencephalographic analysis of seizures induced by intrahippocampal injection of granulitoxin, a neurotoxic peptide from the sea anemone Bunodosoma granulifera.	2001 Jun	11378671
Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies.	2001 Jun 1	11380221
Modulators with convergent cellular actions elicit distinct circuit outputs.	2001 Jun 1	11356892
Agonistic behavior in groups of limbic epileptic male rats: pattern of brain damage and moderating effects from normal rats.	2001 Jun 29	11423076
Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation.	2001 Jun 29	11290736
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents.	2001 Mar	11328682
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model.	2001 Mar	11259499
Reduced excitatory drive onto interneurons in the dentate gyrus after status epilepticus.	2001 Mar 15	11245688
Lithium does not synergize the peripheral action of cholinomimetics as seen in the central nervous system.	2001 Mar 23	11324716
In vivo evaluation of submicron emulsions with pilocarpine: the effect of pH and chemical form of the drug.	2001 Mar-Apr	11253934
Amino acid derivatives with anticonvulsant activity.	2001 May	11383620
Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease.	2001 May	11371395
Lack of effect of mossy fiber-released zinc on granule cell GABA(A) receptors in the pilocarpine model of epilepsy.	2001 May	11353010
Diurnal variation in pilocarpine-induced generalized tonic-clonic seizure activity.	2001 May	11325576
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland.	2001 May 1	11316558
Status epilepticus causes necrotic damage in the mediodorsal nucleus of the thalamus in immature rats.	2001 May 15	11331388
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine.	2001 May 25	11388441

Patents

Sample Use Guides

In Vivo Use Guide

Ophthalmic solution: Instill one drop in the eye(s) up to four times daily. Oral formulation: the recommended dose is 5 mg taken three times a day (Head and Neck Cancer Patients) or 5 mg taken four times a day (Sjogren's Syndrome Patients).

Route of Administration: Other

In Vitro Use Guide

Rat submandibular gland cells were treated wth 100 uM pilocarpine. The drug elicited a small and sustained increase in [Ca2+]i, indicating that pilocarpine acts as a partial agonist for mAChR-mediated Ca2+ responses.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:52:28 UTC 2023` Edited by `admin` on `Wed Jul 05 22:52:28 UTC 2023`
Record UNII	01MI4Q9DI3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Pilocarpine

Common Name

English

PILOCARPINUM [HPUS]

Common Name

English

PILOCARPOL

Common Name

English

2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)-

Systematic Name

English

PILOCARPINE [USP MONOGRAPH]

Common Name

English

PILOCARPINE [MI]

Common Name

English

Pilocarpine [WHO-DD]

Common Name

English

PILOCARPINE [MART.]

Common Name

English

SPERSACARPINE

Common Name

English

OCUCARPINE

Common Name

English

PILOCARPINE [VANDF]

Common Name

English

PILOCARPINE [HSDB]

Common Name

English

PILOCARPINE [USP-RS]

Common Name

English

PILOCARPINE [ORANGE BOOK]

Common Name

English

OCUSERT PILO

Brand Name

English

PILOCARPINE [JAN]

Common Name

English

SYNCARPINE

Common Name

English

PILOKARPIN

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN07AX01